Iovance officer RSUs vest; 2,508 shares withheld

IOVANCE BIOTHERAPEUTICS Chief Regulatory Officer Raj K. Puri reported routine equity compensation activity.

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS Chief Regulatory Officer Raj K. Puri reported routine equity compensation activity. On June 1, 2026, 5,469 restricted stock units (RSUs) vested and converted into the same number of common shares. Of these, 2,508 shares were withheld by the company to cover mandatory tax obligations, which the filing specifies was not an open-market sale. After these transactions, Puri directly holds 242,191 shares of common stock and 16,409 RSUs from the referenced grant, which will continue to vest in equal quarterly installments.

Insider Trade Summary

5,469 shares exercised/converted

Exercise 3 txns

Insider Puri Raj K.

Role Chief Regulatory Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	5,469	$0.00	$0.00
Exercise	Common Stock	5,469	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	2,508	$3.96	$10K

Holdings After Transaction: Restricted Stock Units — 16,409 contracts (Direct); Common Stock — 242,191 shares (Direct)

Footnotes (6)

1. F1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
2. F2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
3. F3. Represents the common stock remaining after deducting the common stock withheld for taxes.
4. F4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
5. F5. The remaining RSUs will vest in equal quarterly installments.
6. F6. Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.

Key Figures

Shares withheld for taxes: 2,508 shares at $3.96 RSUs vested: 5,469 RSUs Common shares after transactions: 242,191 shares +1 more

4 metrics

Shares withheld for taxes 2,508 shares at $3.96 Mandatory tax withholding on RSU vesting, June 1, 2026

RSUs vested 5,469 RSUs Converted into common stock on June 1, 2026

Common shares after transactions 242,191 shares Direct common stock holdings following tax withholding

Remaining RSUs from grant 16,409 RSUs Portion of March 1, 2024 grant still unvested

Key Terms

Restricted Stock Units, mandatory tax withholding requirements, Exercise or conversion of derivative security, contingent right to receive one share

4 terms

Restricted Stock Units financial

"Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding requirements financial

"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs."

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

contingent right to receive one share financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did IOVA’s Chief Regulatory Officer report?

Raj K. Puri reported RSU vesting and related tax withholding. On June 1, 2026, 5,469 restricted stock units vested into common shares, and 2,508 of those shares were withheld by IOVA to satisfy mandatory tax obligations, not sold in the open market.

Did the IOVA insider sell shares in the open market in this Form 4?

No, the Form 4 does not show an open-market sale. The 2,508 shares labeled with code F were withheld by the issuer solely to meet tax withholding requirements upon RSU vesting, which the filing explicitly states is not an open-market sale of securities.

How many IOVA shares does Raj K. Puri hold after these transactions?

After these transactions, Puri holds 242,191 common shares directly. This figure reflects the remaining position after 5,469 RSUs vested into common stock and 2,508 of those shares were withheld by the company to cover mandatory tax obligations.

What happened to the restricted stock units (RSUs) reported for IOVA?

5,469 RSUs vested and converted into common stock on June 1, 2026. Each RSU represented a right to receive one share of IOVANCE common stock. The remaining 16,409 RSUs from the referenced grant will vest in equal quarterly installments over time.

How many RSUs remain outstanding for the IOVA insider after this filing?

Puri has 16,409 remaining RSUs from the March 1, 2024 grant. The filing notes this amount reflects the remainder of that specific RSU grant only and does not include any other RSUs he may hold through separate awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puri Raj K.

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/01/2026		M		5,469	A	$0	244,699	D
Common Stock(2)	06/01/2026		F		2,508	D	$3.96	242,191(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	06/01/2026		M			5,469	(5)	(5)	Common stock	5,469	$0.00	16,409(6)	D

Explanation of Responses:

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.

2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.

3. Represents the common stock remaining after deducting the common stock withheld for taxes.

4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. The remaining RSUs will vest in equal quarterly installments.

6. Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.

	/s/ Raj K. Puri	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)